{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-048027","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2024-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.057469+00:00","generated_at":"2026-06-05T12:07:18.940052+00:00","sec_items":["2.02","8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Absci reports prelim FY2023 revenue $5.7M, cash $97.7M; proposes public offering","bullets":["Preliminary Q4 revenue ~$0.3M, FY revenue ~$5.7M; operating expenses $120-122M incl $21.3M goodwill impairment.","Unrestricted cash/short-term investments $97.7M as of Dec 31, 2023.","Filed preliminary prospectus for underwritten public offering of common stock (undisclosed size).","16 Active Programs with partners including AstraZeneca, Almirall, Merck; ABS-101 IND submission planned Q1 2025.","ABS-101 IND-enabling studies started Feb 2024; Phase 1 potentially H1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-048027","json":"https://secwatch.observer/filing/0001193125-24-048027.json","markdown":"https://secwatch.observer/filing/0001193125-24-048027.md","text":"https://secwatch.observer/filing/0001193125-24-048027.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000119312524048027/0001193125-24-048027-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000119312524048027/d800047d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T12:07:18.940052+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}